Efficacy and Safety Study of Oral CEM-101 Compared to Oral Levofloxacin in Treatment of Patients With Community-Acquired Bacterial Pneumonia

NCT01168713 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

132

Enrollment

INDUSTRY

Sponsor class

Conditions

Community-Acquired Bacterial Pneumonia

Interventions

DRUG: Levofloxacin
DRUG: CEM-101

Sponsor

Melinta Therapeutics, Inc.